Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Pozycja w akcjach #15401
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Cena akcji
$9.50
Kapitalizacja rynkowa
$357.48M
Zmiana (1 dzień)
-0.05%
Zmiana (1 rok)
92.60%
Kraj
US
Handel BioAge Labs Inc. (BIOA)

Kategoria

Wskaźnik P/B dla BioAge Labs Inc. (BIOA)
Wskaźnik P/B na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji BioAge Labs Inc., obecny wskaźnik P/B (TTM) wynosi 0. Na koniec 2026 wynosił 0.
Historia wskaźnika P/B dla BioAge Labs Inc. od 2026 do 2026
Wskaźnik P/B na koniec każdego roku
Rok Wskaźnik P/B Zmień
Za mało danych dla podanych dat.
Wskaźnik P/B dla podobnych firm lub konkurentów
Firma Wskaźnik P/B Różnica wskaźnika P/B Kraj
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH